The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis

1 Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96–102. doi:10.1002/dmrr.2486.

2 Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015;38(12):1153–1168. doi:10.1007/s40264-015-0339-z.

3 Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728–2729. doi:10.2337/dc06-1499.

4 Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid- induced hyperglycemia. J Diabetes. 2014;6(1):9–20. doi:10.1111/1753-0407.12090.

5 Ghazavi MK, Johnston GA. Insulin allergy. Clin Dermatol. 2011;29(3):300–305. doi:10.1016/j.clinderma- tol.2010.11.009.

6 Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019;35(1):e3070. doi:10.1002/dmrr.3070.

7 John B, Matthew C, Eriksson J, et al. Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program. Diabetes. 2020;69 (Supplement 1):930-P. doi:10.2337/ db20-930-P.

8 Hirai H, Ogata E, Kikuchi N, et al. The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report. J Med Case Rep. 2016;10:202. doi:10.1186/s13256-016-0994-4.

9 CONN JW, FAJANS SS. Influence of adrenal cortical steroids on carbohydrate metabolism in man. Metabolism. 1956;5(2):114–127.

10 Mills E, Devendra S. Steroid-induced hyperglycemia in primary care. London J Prim Care (Abingdon). 2015;7(5):103–106. doi:10.1080/17571472.2015.1082344.

11 Zummo FP, Cullen KS, Honkanen-Scott M, Shaw JAM, Lovat PE, Arden C. Glucagon-Like Peptide 1 Protects Pancreatic Beta-Cells from Death by Increasing Autophagic Flux and Restoring Lysosomal Function. Diabetes. 2017;66(5):1272–1285. doi:10.2337/db16-1009.

12 Paternoster S, Falasca M. Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1. Front Endocrinol (Lausanne). 2018;9:584. doi:10.3389/fendo.2018.00584.

13 Ramsey W, Isales CM. Intestinal Incretins and the Regulation of Bone Physiology. Adv Exp Med Biol. 2017;1033:13–33. doi:10.1007/978-3-319-66653-2_2.

14 Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117–2128. doi:10.1056/NEJMoa1916038.

15 Nagai Y, Mori T, Abe T, Nomura G. Immediate-type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient. Endocr J. 2001;48(3):311–316. doi:10.1507/endocrj.48.311.

16 Insuela DBR, Carvalho VF. Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and im- munomodulatory compounds. Eur J Pharmacol. 2017;812:64–72. doi:10.1016/j.ejphar.2017.07.015.

17 Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analog liraglutide on ap- petite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(2):258–266. doi:10.1016/j.diabres.2012.02.016.

18 Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393. doi:10.1056/ NEJMoa021778.

19 Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975–983. doi:10.2337/db08-1193.

20 Deiss D, Diederich S, Kordonouri O. Successful treatment with liraglutide in type 1 diabetes and MODY [in German]. Dtsch Med Wochenschr. 2011;136(21):1116–1120. doi:10.1055/s-0031-1280520.

21 Paisley AN, Savage MW, Wiles PG. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus. Diabet Med. 2009;26(9):935–938. doi:10.1111/j.1464-5491.2009.02789.x.

22 Ritzel RA, Kleine N, Holst JJ, Willms B, Schmiegel W, Nauck MA. Preserved GLP-1 effects in a diabetic patient with Cushing’s disease. Exp Clin Endocrinol Diabetes. 2007;115(2):146–150. doi:10.1055/s-2007-955096.

23 Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J Diabetes. 2010;1(3):99–100. doi:10.4239/wjd.v1.i3.99.

24 Seetho IW, Jones G, Thomson GA, Fernando DJS. Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res Clin Pract. 2011;92(1):e1–e2. doi:10.1016/j.diabres.2010.12.009.

25 Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012;38(1):86–88. doi:10.1016/j.diabet.2011.11.004.